|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-10-10
|
|
pubmed:abstractText |
In several open-label studies, recombinant human interleukin 10 (rhIL-10), a type 2 anti-inflammatory cytokine, has been reported to improve psoriasis, a disease characterized by type 1 cytokine inflammation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0003-987X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
138
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1341-6
|
|
pubmed:dateRevised |
2008-3-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12374540-Adult,
pubmed-meshheading:12374540-Cytokines,
pubmed-meshheading:12374540-Dose-Response Relationship, Drug,
pubmed-meshheading:12374540-Double-Blind Method,
pubmed-meshheading:12374540-Drug Administration Schedule,
pubmed-meshheading:12374540-Female,
pubmed-meshheading:12374540-Flow Cytometry,
pubmed-meshheading:12374540-Follow-Up Studies,
pubmed-meshheading:12374540-Humans,
pubmed-meshheading:12374540-Injections, Subcutaneous,
pubmed-meshheading:12374540-Interleukin-10,
pubmed-meshheading:12374540-Male,
pubmed-meshheading:12374540-Middle Aged,
pubmed-meshheading:12374540-Probability,
pubmed-meshheading:12374540-Psoriasis,
pubmed-meshheading:12374540-Recombination, Genetic,
pubmed-meshheading:12374540-Reference Values,
pubmed-meshheading:12374540-Statistics, Nonparametric,
pubmed-meshheading:12374540-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Clinical and immunologic assessment of patients with psoriasis in a randomized, double-blind, placebo-controlled trial using recombinant human interleukin 10.
|
|
pubmed:affiliation |
Dermatology Branch, National Cancer Institute, Bethesda, MD 20892-1908, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
